AI English summary of an SEC filing — figures as filed
GE HealthCare GEHCThe company said total revenues for the quarter ended March 31, 2024 decreased $4,650 million, or 1% as reported, and were approximately flat organically. It cited the decline in Sales of products, which fell 3%, or $86 million, as the main factor. Total revenues decreased by $57 million in total.
Key points
AI summaryThe company said total revenues for the quarter ended March 31, 2024 decreased $4,650 million, or 1% as reported, and were approximately flat organically. It cited the decline in Sales of products, which fell 3%, or $86 million, as the main factor. Total revenues decreased by $57 million in total.
GE HealthCare said Operating income for the quarter was $540 million, down $19 million. Adjusted EBIT was $681 million (margin 14.7%), up $17 million. The company said R&D investment rose $54 million and SG&A fell $24 million.
The company said cash from operating activities for Q1 2024 was $419 million ($468 million in the same period last year), and free cash flow, after capital expenditures of $145 million, was $274 million.
GE HealthCare said total debt as of March 31, 2024 was $9,255 million, lower than the $9,442 million at December 31, 2023. It said it repaid $150 million of the Term Loan Facility in Q1. The company said senior notes of $1,000 million maturing in November 2024 are included in Short-term borrowings.
Key figures
Quarter ended March 31, 2024
- Revenue
- $4.7B
- Operating income
- $540M
- Net income
- $374M
- EPS
- $0.81
- Gross profit
- $1.9B
- Operating cash flow
- $419M
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Q1 2024 Revenue Down $4,650 million, Product Sales Decline
The company said total revenues for the quarter ended March 31, 2024 decreased $4,650 million, or 1% as reported, and were approximately flat organically. It cited the decline in Sales of products, which fell 3%, or $86 million, as the main factor. Total revenues decreased by $57 million in total.
Source · Based on the MD&A text of the filing
Operating Income $540 million, Adjusted EBIT $681 million
GE HealthCare said Operating income for the quarter was $540 million, down $19 million. Adjusted EBIT was $681 million (margin 14.7%), up $17 million. The company said R&D investment rose $54 million and SG&A fell $24 million.
Source · Based on the MD&A text of the filing
Operating Cash Flow $419 million, Free Cash Flow $274 million
The company said cash from operating activities for Q1 2024 was $419 million ($468 million in the same period last year), and free cash flow, after capital expenditures of $145 million, was $274 million.
Source · Based on the MD&A text of the filing
Total Debt $9,255 million, Term Loan Facility $150 million Repaid
GE HealthCare said total debt as of March 31, 2024 was $9,255 million, lower than the $9,442 million at December 31, 2023. It said it repaid $150 million of the Term Loan Facility in Q1. The company said senior notes of $1,000 million maturing in November 2024 are included in Short-term borrowings.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…